NASDAQ:DVAX - Dynavax Technologies Stock Price, Price Target & More

$18.0750 -0.62 (-3.32 %)

(As of 04/20/2018 04:00 PM ET)

Previous Close$18.0750

Today's Range$17.80 - $18.7250

52-Week Range$5.15 - $24.45

Volume1.29 million shs

Average Volume1.58 million shs

Market Capitalization$1.22 billion

P/E Ratio-10.45

Dividend YieldN/A

Beta0.84

About Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for oncology. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for various immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.

Receive DVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:DVAX

CUSIP26815810

Webwww.dynavax.com

Phone510-848-5100

Debt

Debt-to-Equity RatioN/A

Current Ratio10.65%

Quick Ratio10.64%

Price-To-Earnings

Trailing P/E Ratio-10.45

Forward P/E Ratio-9.46

P/E GrowthN/A

Sales & Book Value

Annual Sales$330,000.00

Price / Sales3,378.38

Cash FlowN/A

Price / CashN/A

Book Value$3.29 per share

Price / Book5.49

Profitability

EPS (Most Recent Fiscal Year)($1.73)

Net Income$-95,150,000.00

Net Margins-29,099.08%

Return on Equity-57.43%

Return on Assets-52.76%

Miscellaneous

Employees170

Outstanding Shares61,680,000

How to Become a New Pot Stock Millionaire

Dynavax Technologies (NASDAQ:DVAX) Frequently Asked Questions

What is Dynavax Technologies' stock symbol?

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Co. (NASDAQ:DVAX) issued its quarterly earnings results on Thursday, March, 8th. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by $0.32. The biopharmaceutical company earned $0.02 million during the quarter, compared to the consensus estimate of $0.53 million. Dynavax Technologies had a negative net margin of 29,099.08% and a negative return on equity of 57.43%. View Dynavax Technologies' Earnings History.

When is Dynavax Technologies' next earnings date?

Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Monday, May, 14th 2018. View Earnings Estimates for Dynavax Technologies.

What price target have analysts set for DVAX?

5 Wall Street analysts have issued 1-year price objectives for Dynavax Technologies' shares. Their forecasts range from $25.00 to $30.00. On average, they expect Dynavax Technologies' stock price to reach $27.40 in the next twelve months. View Analyst Ratings for Dynavax Technologies.

What are Wall Street analysts saying about Dynavax Technologies stock?

Here are some recent quotes from research analysts about Dynavax Technologies stock:

1. Cantor Fitzgerald analysts commented, "HEPLISAV-B Launched. Dynavax reported HEPLISAV-B, a two-dose hepatitis B vaccine, has been launched in the U.S. with a 60-person field sales team (over previous 50-person estimate) covering 75% of the market. HEPLISAV-B was recommended by the CDC for use in the vaccination of adults, which the company believes is critical to drive broad insurance coverage and adoption. As previously reported, the company has a drug supply of over 250,000 vials, with an additional 750,000 vials worth of raw material. We believe this is supply is sufficient for over two years." (3/8/2018)
2. According to Zacks Investment Research, "Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. " (1/10/2018)
3. Cowen Inc analysts commented, "Dynavax reported a Q3 net loss of $22.1MM and ended the quarter with $192MM in." (11/3/2017)

Who are some of Dynavax Technologies' key competitors?

Some companies that are related to Dynavax Technologies include Akorn (AKRX), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), The Medicines (MDCO), AnaptysBio (ANAB), Portola Pharmaceuticals (PTLA), Heron Therapeutics (HRTX), Motif (MTFB), Intercept Pharmaceuticals (ICPT), Corcept Therapeutics (CORT), Spectrum Pharmaceuticals (SPPI), Esperion Therapeutics (ESPR), Arena Pharmaceuticals (ARNA), Aimmune Therapeutics (AIMT), Insmed (INSM), Cambrex (CBM), OPKO Health (OPK) and MyoKardia (MYOK).

Who are Dynavax Technologies' key executives?

Dynavax Technologies' management team includes the folowing people:

Mr. Eddie Gray, CEO & Director (Age 59)
Dr. Dennis A. Carson, Co-Founder & Director (Age 71)
Mr. Michael S. Ostrach, CFO, Chief Bus. Officer & Sr. VP (Age 66)
Mr. David F. Novack, Sr. VP of Operations and Quality (Age 56)
Dr. Robert L. Coffman Ph.D., Chief Scientific Officer and Sr. VP (Age 71)

Has Dynavax Technologies been receiving favorable news coverage?

Headlines about DVAX stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Dynavax Technologies earned a media sentiment score of 0.23 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 44.94 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Dynavax Technologies?

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dynavax Technologies' stock price today?

One share of DVAX stock can currently be purchased for approximately $18.0750.

How big of a company is Dynavax Technologies?

Dynavax Technologies has a market capitalization of $1.22 billion and generates $330,000.00 in revenue each year. The biopharmaceutical company earns $-95,150,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. Dynavax Technologies employs 170 workers across the globe.

How can I contact Dynavax Technologies?

Dynavax Technologies' mailing address is 2929 SEVENTH STREET SUITE 100, BERKELEY CA, 94710. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]

MarketBeat Community Rating for Dynavax Technologies (DVAX)

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		254 (Vote Outperform)
Underperform Votes:		235 (Vote Underperform)
Total Votes:		489

MarketBeat's community ratings are surveys of what our community members think about Dynavax Technologies and other stocks. Vote "Outperform" if you believe DVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Dynavax Technologies (NASDAQ:DVAX) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

5 Wall Street analysts have issued ratings and price targets for Dynavax Technologies in the last 12 months. Their average twelve-month price target is $27.40, suggesting that the stock has a possible upside of 51.59%. The high price target for DVAX is $30.00 and the low price target for DVAX is $25.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.80	2.80	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$27.40	$27.40	$28.00	$27.80
Price Target Upside:	51.59% upside	52.22% upside	39.65% upside	35.61% upside

Dynavax Technologies (NASDAQ:DVAX) Consensus Price Target History

Price Target History for Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies (NASDAQ:DVAX) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/16/2018	Cantor Fitzgerald	Set Price Target	Buy	$27.00	High
3/9/2018	Royal Bank of Canada	Reiterated Rating	Buy	$25.00	Medium
2/21/2018	Cowen	Reiterated Rating	Buy	$30.00	Low
2/14/2018	JPMorgan Chase	Downgrade	Overweight -> Neutral	$31.00 -> $25.00	Medium
8/9/2017	William Blair	Reiterated Rating	Outperform	$30.00	High
9/2/2016	S&P Equity Research	Boost Price Target		$11.28 -> $16.01	N/A

(Data available from 4/20/2016 forward)

Dynavax Technologies (NASDAQ:DVAX) Earnings History and Estimates Chart

Earnings by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies (NASDAQ:DVAX) Earnings Estimates

2018 EPS Consensus Estimate: ($1.67)
2019 EPS Consensus Estimate: ($0.53)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.47)	($0.47)	($0.47)
Q2 2018	1	($0.45)	($0.45)	($0.45)
Q3 2018	1	($0.42)	($0.42)	($0.42)
Q4 2018	1	($0.33)	($0.33)	($0.33)
Q1 2019	1	($0.27)	($0.27)	($0.27)
Q2 2019	1	($0.18)	($0.18)	($0.18)
Q3 2019	1	($0.09)	($0.09)	($0.09)
Q4 2019	1	$0.01	$0.01	$0.01

Dynavax Technologies (NASDAQ DVAX) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/7/2018		($0.43)					N/A
3/8/2018	Q4 2017	($0.11)	($0.43)	$0.53 million	$0.02 million	View	N/A
11/3/2017	Q3 2017	($0.53)	($0.38)	$0.28 million	$0.05 million	View	N/A
8/2/2017	Q2 2017	($0.50)	($0.41)	$0.15 million	$0.11 million	View	N/A
5/8/2017	Q1 2017	($0.60)	($0.60)	$0.75 million	$0.15 million	View	N/A
3/13/2017	Q4 2016	($0.85)	($0.56)	$2.90 million	$7.30 million	View	N/A
11/7/2016	Q3	($0.75)	($0.90)	$2.44 million	$0.20 million	View	N/A
8/5/2016	Q2	($0.68)	($0.75)	$1.58 million	$2.65 million	View	N/A
5/9/2016	Q1	($0.63)	($0.70)	$627.00 million	$942.00 million	View	N/A
3/8/2016	Q4	($0.75)	($0.70)	$1.15 million	$0.69 million	View	N/A
11/5/2015	Q3	($0.78)	($0.82)	$1.65 million	$1.20 million	View	N/A
8/7/2015	Q2	($1.00)	($0.80)	$3.05 million	$1.55 million	View	N/A
5/7/2015	Q1 2015	($0.95)	($0.97)	$1.26 million	$0.63 million	View	N/A
3/5/2015	Q4 2014	($1.06)	($0.85)	$2.15 million	$2.28 million	View	N/A
11/5/2014	Q314	($0.09)	($0.11)	$2.50 million	$2.21 million	View	N/A
8/7/2014	Q214	($0.06)	($0.09)	$2.26 million	$3.05 million	View	N/A
5/5/2014	Q1 2014	($0.06)	($0.05)	$4.22 million	$3.50 million	View	N/A
3/10/2014	Q413	($0.07)	($0.09)	$1.56 million	$2.80 million	View	N/A
11/7/2013	Q313	($0.10)	($0.09)	$1.83 million	$2.93 million	View	N/A
7/29/2013	Q2 2013	($0.10)	($0.09)	$2.91 million	$3.40 million	View	N/A
5/6/2013	Q113	($0.11)	($0.11)	$2.40 million	$2.10 million	View	N/A
3/1/2013	Q4 2012		($0.11)	$11.40 million	$1.80 million	View	N/A
11/1/2012	Q312	($0.08)	($0.10)	$5.00 million	$2.90 million	View	N/A
8/1/2012	Q2 2012	($1.00)	($0.90)			View	N/A
4/27/2012	Q1 2012	($0.80)	($1.06)			View	N/A
3/6/2012	Q4 2011	($0.70)	($0.30)			View	N/A
10/27/2011	Q3 2011	($1.30)	($1.23)			View	N/A
7/20/2011	Q2 2011	($1.10)	($0.90)			View	N/A
5/5/2011	Q1 2011	($1.50)	($1.58)			View	N/A
3/8/2011	Q4 2010	($1.40)	($1.43)			View	N/A
11/4/2010	Q3 2010	($0.30)	($0.55)			View	N/A
7/30/2010	Q2 2010	($1.30)	($3.41)			View	N/A
5/6/2010	Q1 2010		($1.69)			View	N/A
3/16/2010	Q4 2009		($7.31)			View	N/A
10/22/2009	Q3 2009	($2.40)	($2.37)			View	N/A
8/4/2009	Q2 2009	$0.40	$1.03			View	N/A
4/28/2009	Q1 2009	($0.20)	$1.28			View	N/A
3/2/2009	Q4 2008	($0.60)	$0.78			View	N/A
11/3/2008	Q3 2008	($1.10)	($1.36)			View	N/A
8/5/2008	Q2 2008	($2.40)	($1.53)			View	N/A
4/29/2008	Q1 2008	($2.30)	($3.12)			View	N/A
2/19/2008	Q4 2007	($3.40)	($3.04)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Dynavax Technologies (NASDAQ:DVAX) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Dynavax Technologies (NASDAQ DVAX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.90%
Institutional Ownership Percentage: 71.23%

Insider Trading History for Dynavax Technologies (NASDAQ:DVAX)

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies (NASDAQ DVAX) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/15/2018	David F Novack	Insider	Sell	16,109	$16.30	$262,576.70
3/13/2018	David F Novack	Insider	Sell	34,214	$16.52	$565,215.28	21,613
3/9/2018	David F Novack	Insider	Sell	2,121	$17.97	$38,114.37	77,192
1/4/2018	David Louis Johnson	VP	Sell	3,092	$18.60	$57,511.20	7,780
12/13/2017	Robert Coffman	Insider	Sell	7,500	$18.90	$141,750.00
1/24/2017	Robert Janssen	VP	Buy	6,000	$4.04	$24,240.00	12,048
6/28/2016	Robert Janssen	VP	Buy	1,452	$13.68	$19,863.36	6,048
5/20/2016	Eddie Gray	CEO	Buy	2,750	$15.57	$42,817.50	5,050
5/12/2016	Robert Janssen	VP	Buy	1,000	$15.12	$15,120.00	1,000
8/14/2014	Eddie Gray	CEO	Buy	25,000	$1.49	$37,250.00
10/30/2013	Peggy V Phillips	Director	Buy	93,023	$1.08	$100,464.84
9/14/2012	Jennifer Lew	VP	Sell	18,750	$4.53	$84,937.50
9/13/2012	Robert Coffman	VP	Sell	8,000	$4.52	$36,160.00

(Data available from 1/1/2013 forward)

Dynavax Technologies (NASDAQ DVAX) News Headlines

Source:

Date	Headline
	$820,000.00 in Sales Expected for Dynavax Technologies Co. (DVAX) This Quarter www.americanbankingnews.com - April 20 at 4:25 AM
	Pre-Open Stock Movers 04/16: (ERI) (ALKS) (DVAX) Higher; (CLDX) (ALGT) (NLNK) Lower (more...) www.streetinsider.com - April 18 at 4:40 PM
	-$0.51 EPS Expected for Dynavax Technologies Co. (DVAX) This Quarter www.americanbankingnews.com - April 18 at 9:35 AM
	Dynavax: Positive Results, Market Confusion seekingalpha.com - April 18 at 9:27 AM
	Brokers Issue Forecasts for Dynavax Technologies Co.'s Q1 2019 Earnings (DVAX) www.americanbankingnews.com - April 18 at 8:42 AM
	Dynavax Provides New Durability of Response Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Melanoma at the 2018 American Association for Cancer Research Annual Meeting finance.yahoo.com - April 17 at 9:19 AM
	Dynavax Technologies (DVAX) Given a $27.00 Price Target by Cantor Fitzgerald Analysts www.americanbankingnews.com - April 16 at 6:30 PM
	Investors bullish on early-stage data on Dynavax's SD-101 + Keytruda in advanced melanoma; shares up 14% premarket seekingalpha.com - April 16 at 9:34 AM
	Dynavax shares rise 14% on promising cancer conference data finance.yahoo.com - April 16 at 9:34 AM
	Dynavax Technologies (DVAX) Rating Increased to Buy at BidaskClub www.americanbankingnews.com - April 16 at 7:00 AM
	Dynavax Technologies (DVAX) PT Set at $7.00 by Royal Bank of Canada www.americanbankingnews.com - April 15 at 5:39 PM
	Dynavax Technologies (DVAX) Upgraded to "Outperform" by Royal Bank of Canada www.americanbankingnews.com - April 15 at 9:45 AM
	Dynavax Technologies (DVAX) Rating Increased to Overweight at JPMorgan Chase www.americanbankingnews.com - April 15 at 9:43 AM
	Dynavax Technologies (DVAX) Cut to "Hold" at BidaskClub www.americanbankingnews.com - April 14 at 11:26 PM
	Investors Buy High Volume of Put Options on Dynavax Technologies (DVAX) www.americanbankingnews.com - April 12 at 7:01 AM
	Dynavax Technologies' (DVAX) "Outperform" Rating Reaffirmed at Cowen www.americanbankingnews.com - April 11 at 5:01 PM
	Dynavax Technologies (DVAX) Rating Lowered to Hold at BidaskClub www.americanbankingnews.com - April 10 at 10:24 AM
	Dynavax Technologies Co. (DVAX) Receives Consensus Recommendation of "Buy" from Brokerages www.americanbankingnews.com - April 7 at 1:29 AM
	Watch These April Biotech Catalysts seekingalpha.com - April 3 at 9:10 AM
	Dynavax Technologies Co. (DVAX) Expected to Post Earnings of -$0.51 Per Share www.americanbankingnews.com - April 1 at 7:22 AM
	Dynavax Technologies (DVAX) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - March 28 at 9:49 PM
	What Are Analysts Saying About The Future Of Dynavax Technologies Corporation’s (NASDAQ:DVAX)? finance.yahoo.com - March 28 at 8:59 AM
	Dynavax Technologies (DVAX) Raised to Buy at BidaskClub www.americanbankingnews.com - March 27 at 5:10 PM
	Dynavax Technologies (DVAX) Stock Rating Upgraded by ValuEngine www.americanbankingnews.com - March 27 at 10:01 AM
	Dynavax Technologies (DVAX) Raised to "Hold" at BidaskClub www.americanbankingnews.com - March 25 at 3:12 PM
	Reviewing Dynavax Technologies (DVAX) and Strongbridge Biopharma (SBBP) www.americanbankingnews.com - March 24 at 1:49 PM
	Dynavax Announces Acceptance of Two Data Abstracts for SD-101 in Combination with KEYTRUDA® for Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting finance.yahoo.com - March 23 at 8:54 AM
	Sonoma Pharmaceuticals (SNOA) versus Dynavax Technologies (DVAX) Financial Survey www.americanbankingnews.com - March 17 at 9:48 AM
	Zacks: Analysts Expect Dynavax Technologies Co. (DVAX) Will Post Quarterly Sales of $820,000.00 www.americanbankingnews.com - March 17 at 9:01 AM
	Insider Selling: Dynavax Technologies Co. (DVAX) Insider Sells 16,109 Shares of Stock www.americanbankingnews.com - March 16 at 8:14 PM
	Insider Selling: Dynavax Technologies Co. (DVAX) Insider Sells 34,214 Shares of Stock www.americanbankingnews.com - March 15 at 10:08 PM
	Cantor Fitzgerald Weighs in on Dynavax Technologies Co.'s FY2018 Earnings (DVAX) www.americanbankingnews.com - March 14 at 10:06 AM
	David F. Novack Sells 2,121 Shares of Dynavax Technologies Co. (DVAX) Stock www.americanbankingnews.com - March 13 at 8:51 PM
	Dynavax Technologies Co. (DVAX) Given Consensus Recommendation of "Hold" by Analysts www.americanbankingnews.com - March 13 at 1:46 AM
	Dynavax Technologies (DVAX) Given "Buy" Rating at Royal Bank of Canada www.americanbankingnews.com - March 10 at 4:20 PM
	Dynavax Technologies (DVAX) Announces Earnings Results www.americanbankingnews.com - March 9 at 2:03 PM
	Dynavax Technologies' (DVAX) Buy Rating Reaffirmed at Cantor Fitzgerald www.americanbankingnews.com - March 8 at 7:03 PM
	Dynavax Reports Fourth Quarter and Year End 2017 Financial Results finance.yahoo.com - March 8 at 10:21 AM
	Dynavax to Present at the Cowen & Co. Annual Health Care Conference finance.yahoo.com - March 5 at 4:50 PM
	Dynavax Technologies Co. (DVAX) Position Lifted by State of Wisconsin Investment Board www.americanbankingnews.com - March 5 at 9:43 AM
	Dynavax Technologies (DVAX) Scheduled to Post Earnings on Monday www.americanbankingnews.com - March 5 at 2:16 AM
	Senvest Management LLC Purchases 349,288 Shares of Dynavax Technologies Co. (DVAX) www.americanbankingnews.com - February 26 at 12:44 PM
	Dynavax Technologies Co. (DVAX) to Post Q1 2018 Earnings of ($0.47) Per Share, William Blair Forecasts www.americanbankingnews.com - February 26 at 2:58 AM
	Your Daily Pharma Scoop: Dynavax Achieves Major Milestone, GW Pharmaceuticals GWP42006 Fails, Sangamo Signs Deal With Gilead's Kite Unit seekingalpha.com - February 23 at 9:18 AM
	Dynavax Technologies (DVAX) Receives "Buy" Rating from Cowen www.americanbankingnews.com - February 21 at 8:16 PM
	Dynavax (DVAX) HEPLISAV-B Recommended by CDC Advisory Committee on Immunization Practices for Prevention of Hepatitis B in Adults www.streetinsider.com - February 21 at 4:55 PM
	Dynavax Pops With CDC Recommendation www.msn.com - February 21 at 4:55 PM
	Dynavax stock rises after hepatitis B vaccine recommendation by CDC immunization committee finance.yahoo.com - February 21 at 4:55 PM
	US panel recommends new adult vaccine against hepatitis B finance.yahoo.com - February 21 at 4:55 PM
	Dynavax’s HEPLISAV-B™ Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults finance.yahoo.com - February 21 at 9:39 AM

Dynavax Technologies (NASDAQ:DVAX) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Dynavax Technologies (NASDAQ:DVAX) Income Statement, Balance Sheet and Cash Flow Statement

Dynavax Technologies (NASDAQ DVAX) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff